Effect of medication therapy management by pharmaceutical care on blood pressure and cardiovascular risk in hypertension: a systematic review, meta-analysis, and meta-regression

de Souza Cazarim, M., Cruz-Cazarim, E. L. C., Boyd, K. , Wu, O. and Nunes, A. A. (2023) Effect of medication therapy management by pharmaceutical care on blood pressure and cardiovascular risk in hypertension: a systematic review, meta-analysis, and meta-regression. Pharmaceuticals, 16(6), 845. (doi: 10.3390/ph16060845) (PMID:37375792) (PMCID:PMC10302324)

[img] Text
300815.pdf - Published Version
Available under License Creative Commons Attribution.

5MB

Abstract

Medication therapy management by pharmaceutical care (MTM-PC) has been shown to improve the effectiveness of antihypertensive treatments. The aim was to answer the question: what are the MTM-PC models and their impact on hypertensive patients’ outcomes? This is a systematic review with meta-analysis. The search strategies were run on 27 September 2022 in the following databases: PubMed, EMBASE, Scopus, LILACs, Central Cochrane Library, Web of Science; and International Pharmaceutical Abstracts. The quality and bias risk was assessed by the Downs and Black instrument. Forty-one studies met the eligibility criteria and were included, Kappa = 0.86; 95% CI, 0.66–1.0; (p < 0.001). Twenty-seven studies (65.9%) had MTM-PC models outlined by the clinical team, showing as characteristics the mean of 10.0 ± 10.7 months of follow-up of hypertensive patients, with 7.7 ± 4.9 consultations. Instruments to assess the quality of life measured the enhancement by 13.4 ± 10.7% (p = 0.047). The findings of the meta-analysis show a mean reduction of −7.71 (95% CI, −10.93 to −4.48) and −3.66 (95% CI, −5.51 to −1.80), (p < 0.001) in mmHg systolic and diastolic pressures, respectively. Cardiovascular relative risk (RR) over ten years was 0.561 (95% CI, 0.422 to 0.742) and RR = 0.570 (95% CI, 0.431 to 0.750), considering homogeneous studies, I² = 0%. This study shows the prevalence of MTM-PC models outlined by the clinical team, in which there are differences according to the models in reducing blood pressure and cardiovascular risk over ten years with the improvement in quality of life.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Wu, Professor Olivia and Boyd, Professor Kathleen
Authors: de Souza Cazarim, M., Cruz-Cazarim, E. L. C., Boyd, K., Wu, O., and Nunes, A. A.
College/School:College of Medical Veterinary and Life Sciences > School of Health & Wellbeing > Health Economics and Health Technology Assessment
Journal Name:Pharmaceuticals
Publisher:MDPI
ISSN:1424-8247
ISSN (Online):1424-8247
Published Online:06 June 2023
Copyright Holders:Copyright © 2023 by the authors.
First Published:First published in Pharmaceuticals 16(16):845
Publisher Policy:Reproduced under a Creative Commons license

University Staff: Request a correction | Enlighten Editors: Update this record